Power Law company profile

Shenzhen Salubris Pharmaceuticals

Biotech & Life Sciences · Shenzhen, China · Founded 1998 · IPO 2009 Unicorn

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a professional pharmaceutical enterprise rooted in China and devoted to improving health worldwide

Valuation

$7.70B

Market cap · May/2026

Revenue

$552M

Latest reported FY

EBITDA

$167M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Global footprint

Where Shenzhen Salubris Pharmaceuticals has talent and traffic

Workforce by country

6 countries with
team presence

🇨🇳 China95.4%

🇺🇸 United States2.2%

🇩🇿 Algeria0.6%

🇻🇳 Vietnam0.6%

🇳🇬 Nigeria0.6%

Top 5 of 6 shown

Patent intelligence

$37M patent portfolio · 208 active families

Estimated portfolio value

$37M

0.47% of market cap · 6.3× smaller than top peer Galapagos ($230M)

208 active patent families

Where Shenzhen Salubris Pharmaceuticals innovates Pharmaceutical drugDiseaseMolecular biologyPharmaceutical SubstancesMedicinal chemistry

Where Shenzhen Salubris Pharmaceuticals concentrates vs peers

Each axis is a top-10 topic across Shenzhen Salubris Pharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Shenzhen Salubris Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Shenzhen Salubris Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Shenzhen Salubris Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles